Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 269Neoplasms 148Breast Neoplasms 146Colorectal Neoplasms 128Neoplasm Metastasis 96Prostatic Neoplasms 95Multiple Myeloma 94Ovarian Neoplasms 93Lung Neoplasms 88Squamous Cell Carcinoma of Head and Neck 64Pancreatic Neoplasms 64Recurrence 62Endometrial Neoplasms 58Small Cell Lung Carcinoma 52Melanoma 52Stomach Neoplasms 50Leukemia, Lymphocytic, Chronic, B-Cell 48Carcinoma, Renal Cell 47Leukemia, Myeloid, Acute 46Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 40Urinary Bladder Neoplasms 38Triple Negative Breast Neoplasms 38Parkinson Disease 4, Autosomal Dominant Lewy Body 38Head and Neck Neoplasms 38Lymphoma, Large B-Cell, Diffuse 36Carcinoma, Hepatocellular 35Esophageal Neoplasms 32Lymphoma, Follicular 30Colonic Neoplasms 29

Interventions

Paracentesis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Malignant Ascites × 30 days × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡